Friday, 6 November 2026European Markets

BENFICA, UMG, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Entertainment Industry.

Loading stream...

(VIANEWS) - BENFICA (SLBEN.LS) is among this list of stock assets with the highest dividend rate and return on equity on the Entertainment industry.

Financial Asset Price Forward Dividend Yield Return on Equity
BENFICA (SLBEN.LS) €2.97 3.92% 3.79%
UMG (UMG.AS) €25.75 1.96% 49.11%
AJAX (AJAX.AS) €10.05 0.88% 17.95%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. BENFICA (SLBEN.LS)

3.92% Forward Dividend Yield and 3.79% Return On Equity

Sport Lisboa e Benfica - Futebol, SAD operates a sports club in Portugal. The company was founded in 1904 and is headquartered in Lisbon, Portugal. Sport Lisboa e Benfica - Futebol, SAD operates as a subsidiary of Sport Lisboa e Benfica SGPS SA.

Earnings Per Share

As for profitability, BENFICA has a trailing twelve months EPS of €0.18.

PE Ratio

BENFICA has a trailing twelve months price to earnings ratio of 16.5. Meaning, the purchaser of the share is investing €16.5 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.79%.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on Jan 1, 1970, the estimated forward annual dividend yield is 3.92%.

Moving Average

BENFICA's worth is way below its 50-day moving average of €3.38 and way below its 200-day moving average of €3.66.

Yearly Top and Bottom Value

BENFICA's stock is valued at €2.97 at 21:40 EST, way under its 52-week high of €4.14 and above its 52-week low of €2.76.

More news about BENFICA.

2. UMG (UMG.AS)

1.96% Forward Dividend Yield and 49.11% Return On Equity

Universal Music Group N.V. operates as a music company worldwide. It operates through Recorded Music, Music Publishing, and Merchandising & Other segments. The Recorded Music segment discovers and develops recording artists, as well as markets and promotes their music across various formats and platforms; and engages in the live events, sponsorship, film, and television operations. The Music Publishing segment discovers and develops songwriters, as well as owns and administers the copyright for musical compositions used in recordings, public performances, and related uses, such as films and advertisements. The Merchandising & Other segment produces and sells artist and other branded products through various sales channels, including fashion retail, concert touring, and internet, as well as offers brand rights management services. The company has approximately 3 million recordings, 4 million owned and administered titles, and 220 artists/brands, as well as owns approximately 50 labels covering various music genres. Universal Music Group N.V. was incorporated in 2020 and is headquartered in Hilversum, the Netherlands.

Earnings Per Share

As for profitability, UMG has a trailing twelve months EPS of €0.64.

PE Ratio

UMG has a trailing twelve months price to earnings ratio of 40.23. Meaning, the purchaser of the share is investing €40.23 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 49.11%.

Moving Average

UMG's value is higher than its 50-day moving average of €24.42 and way higher than its 200-day moving average of €22.29.

Revenue Growth

Year-on-year quarterly revenue growth grew by 8.7%, now sitting on 10.75B for the twelve trailing months.

More news about UMG.

3. AJAX (AJAX.AS)

0.88% Forward Dividend Yield and 17.95% Return On Equity

AFC Ajax NV operates a football club primarily in the Netherlands. It also operates a stadium and an youth academy. The company was founded in 1900 and is based in Amsterdam, the Netherlands.

Earnings Per Share

As for profitability, AJAX has a trailing twelve months EPS of €2.13.

PE Ratio

AJAX has a trailing twelve months price to earnings ratio of 4.72. Meaning, the purchaser of the share is investing €4.72 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.95%.

Moving Average

AJAX's worth is below its 50-day moving average of €10.76 and below its 200-day moving average of €10.87.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AJAX's stock is considered to be overbought (>=80).

Sales Growth

AJAX's sales growth is 1.5% for the current quarter and 1.5% for the next.

Volatility

AJAX's last week, last month's, and last quarter's current intraday variation average was a negative 1.34%, a negative 0.31%, and a positive 1.26%.

AJAX's highest amplitude of average volatility was 1.34% (last week), 1.07% (last month), and 1.26% (last quarter).

More news about AJAX.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com